…Destroys N22.73 billion Worth of Unsafe Products
The National Agency for Food and Drug Administration and Control (NAFDAC) says it recorded significant progress in regulatory enforcement, digital innovation, local pharmaceutical manufacturing and international collaboration in 2026.
In a statement by its Resident Media & Communication Consultant, Sayo Akintola, on Sunday, the agency disclosed this during its regulatory update presentation at the International Pharmaceutical Regulators Programme (IPRP) Management Committee Meeting held in Prague, Czech Republic, from November 18 to 19, 2026.
A major highlight of the agency’s achievements is its sustained World Health Organisation (WHO) Maturity Level 3 status and ongoing efforts to attain Maturity Level 4, the highest rating under the WHO Global Benchmarking Tool.
NAFDAC said it had introduced several digital initiatives to strengthen regulatory efficiency and transparency, including the Integrated Regulatory Information Management System (IRIMS), Performance Management System (i-PMS), Good Manufacturing Practice (GMP) Inspection Application and AI-assisted Technical Screening Tools.
The agency also highlighted the revision of its Med Safety App to improve the reporting of substandard and falsified medical products, as well as adverse drug reactions across the country.
On enforcement, NAFDAC said it carried out 5,542 enforcement activities between January and August 2026, resulting in 213 raids, 821 product seizures, the closure of 179 premises, 52 arrests and 221 sanctions.
It added that unwholesome products valued at approximately N22.73 billion were destroyed during 22 separate destruction exercises within the period.
The agency also reported progress in promoting domestic pharmaceutical production through its 5+5 Policy, disclosing that more than 70 per cent of finished pharmaceutical products covered under the policy and Ceiling 36 were now being manufactured locally.
The initiative is designed to reduce Nigeria’s dependence on imported medicines, encourage local investment and strengthen the country’s pharmaceutical manufacturing capacity.
On the international front, NAFDAC said its growing regulatory capacity had earned it recognition as a reference National Regulatory Authority, with regulatory agencies from Uganda, The Gambia, Mozambique and Côte d’Ivoire visiting Nigeria for technical capacity building and institutional benchmarking.
Nigeria also ratified the African Medicines Agency (AMA) Treaty and deposited its instruments of ratification on October 25, 2026, a development expected to support regional cooperation and harmonisation of medicines regulation across Africa.
The agency attributed the milestones to the leadership of its Director-General, Prof. Mojisola Christianah Adeyeye, saying her administration had continued to prioritise institutional reforms, science-based regulation, digital transformation and international cooperation.
NAFDAC said it would sustain efforts to strengthen regulatory systems, protect public health and consolidate Nigeria’s position as a leading regulatory authority on the African continent.
